达巴万星治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）患者的疗效及其对住院和治疗费用的影响。
The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.
作者信息
Carbonara Sergio
机构信息
Unità Operativa Complessa di Malattie Infettive, Ospedale Vittorio Emanuele II, Bisceglie - Italy.
出版信息
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):13-17. doi: 10.33393/grhta.2024.3045. eCollection 2024 Jan-Dec.
Abstract
Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.
摘要
急性细菌性皮肤和皮肤结构感染（ABSSSIs）是一种常见且成本高昂的医疗负担，每年导致数百万例感染，医疗支出达数十亿美元。达巴万星是一种长效糖肽类抗生素，已证明在治疗ABSSSIs方面具有疗效和安全性。这篇综述文章将研究达巴万星的疗效，并重点关注其对住院时间以及这些感染管理相关成本的影响。
相似文献
1
The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):13-17. doi: 10.33393/grhta.2024.3045. eCollection 2024 Jan-Dec.
2
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Clin Drug Investig. 2020 Apr;40(4):305-318. doi: 10.1007/s40261-020-00891-w.
3
Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Infez Med. 2024 Jun 1;32(2):231-240. doi: 10.53854/liim-3202-11. eCollection 2024.
4
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Expert Rev Anti Infect Ther. 2020 Dec;18(12):1271-1279. doi: 10.1080/14787210.2020.1798227. Epub 2020 Aug 14.
5
Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network.
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):5-12. doi: 10.33393/grhta.2024.3094. eCollection 2024 Jan-Dec.
6
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):703-721. doi: 10.1080/14787210.2023.2214727. Epub 2023 May 31.
7
REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8.
8
Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Clin Infect Dis. 2021 Oct 5;73(7):e1436-e1442. doi: 10.1093/cid/ciaa1732.
9
The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Expert Rev Anti Infect Ther. 2020 May;18(5):415-422. doi: 10.1080/14787210.2020.1746643. Epub 2020 Mar 29.
10
Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Children (Basel). 2024 Jan 9;11(1):78. doi: 10.3390/children11010078.
本文引用的文献
1
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):703-721. doi: 10.1080/14787210.2023.2214727. Epub 2023 May 31.
2
Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.
JAC Antimicrob Resist. 2023 Apr 19;5(2):dlad044. doi: 10.1093/jacamr/dlad044. eCollection 2023 Apr.
3
REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8.
4
Real world utilization of Dalbavancin at a rural community emergency department.
Am J Emerg Med. 2022 Apr;54:253-256. doi: 10.1016/j.ajem.2022.02.006. Epub 2022 Feb 6.
5
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Clin Drug Investig. 2021 May;41(5):437-448. doi: 10.1007/s40261-021-01028-3. Epub 2021 Apr 21.
6
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Ther Clin Risk Manag. 2021 Mar 22;17:223-232. doi: 10.2147/TCRM.S271445. eCollection 2021.
7
Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.
Acad Emerg Med. 2021 Oct;28(10):1108-1117. doi: 10.1111/acem.14258. Epub 2021 May 5.
8
Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
Eur J Hosp Pharm. 2022 Jan;29(1):55-58. doi: 10.1136/ejhpharm-2020-002315. Epub 2020 Oct 5.
9
Current trends in the real-life use of dalbavancin: report of a study panel.
Int J Antimicrob Agents. 2020 Oct;56(4):106107. doi: 10.1016/j.ijantimicag.2020.106107. Epub 2020 Jul 25.
10
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Clin Drug Investig. 2020 Apr;40(4):305-318. doi: 10.1007/s40261-020-00891-w.
Zotero 插件